YHYue Hua

Yue Hua

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yue Hua has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Anqi Zhou

    California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, USA

    2 shared publications
  • Dongping Qi

    Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, USA

    2 shared publications
  • Hsian-Rong Tseng

    California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology

    2 shared publications
  • Jiantong Dong

    Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel

    2 shared publications
  • Matthew Smalley

    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, CA 90095, USA

    2 shared publications
  • Meiping Zhao

    Beijing National Laboratory for Molecular Sciences and MOE Key Laboratory of Bioorganic Chemistry and Molecular Engineering, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China

    2 shared publications

Latest Publications

  • Open Access

    Racial and ethnic differences in second primary lung cancer risk among lung cancer survivors

    by Eunji Choi, Yue Hua, Chloe C Su, Julie T Wu, Joel W Neal, Ann N Leung, Leah M Backhus, Christopher Haiman, Loïc Le Marchand, Su-Ying Liang, et al.

    Recent therapeutic advances have improved survival among lung cancer (LC) patients, who are now at high risk of second primary lung cancer (SPLC). Hispanics comprise the largest minority in the United States, who have shown a lower LC incidence and mortality than other races, and yet their SPLC risk is poorly understood. We quantified the SPLC incidence patterns among Hispanics vs other races. We used data from the Multiethnic Cohort, a population-based cohort of 5 races (African American, Japanese American, Hispanic, Native Hawaiian, and White), recruited between 1993 and 1996 and followed through 2017. We identified patients diagnosed with initial primary lung cancer (IPLC) and SPLC via linkage to Surveillance, Epidemiology, and End Results registries. We estimated the 10-year cumulative incidence of IPLC (in the entire cohort) and SPLC (among IPLC patients). A standardized incidence ratio (SIR) was calculated as the ratio of SPLC-to-IPLC incidence by race and ethnicity. Among 202 692 participants, 6788 (3.3%) developed IPLC over 3 871 417 person-years. The 10-year cumulative IPLC incidence was lower among Hispanics (0.80%, 0.72 to 0.88) vs Whites (1.67%, 1.56 to 1.78) or Blacks (2.44%, 2.28 to 2.60). However, the 10-year SPLC incidence following IPLC was higher among Hispanics (3.11%, 1.62 to 4.61) vs Whites (2.80%, 1.94 to 3.66) or Blacks (2.29%, 1.48 to 3.10), resulting in a significantly higher SIR for Hispanics (SIR = 8.27, 5.05 to 12.78) vs Whites (SIR = 5.60, 4.11 to 7.45) or Blacks (SIR = 3.48, 2.42 to 4.84; P < .001). Hispanics have a higher SPLC incidence following IPLC than other races, which may be potentially due to better survival after IPLC and extended duration for SPLC development. Continuing surveillance is warranted to reduce racial disparities among LC survivors.


  • Coupling Nanostructured Microchips with Covalent Chemistry Enables Purification of Sarcoma‐Derived Extracellular Vesicles for Downstream Functional Studies

    by Jiantong Dong, Ryan Y. Zhang, Na Sun, Junhui Hu, Matthew D. Smalley, Anqi Zhou, Yue Hua, Winston Rothermich, Mengxiang Chen, Jiayuan Chen, et al.

    Tumor‐derived extracellular vesicles (EVs) play essential roles in intercellular communication during tumor growth and metastatic evolution. Currently, little is known about the possible roles of tumor‐derived EVs in sarcoma because the lack of specific surface markers makes it technically challenging to purify sarcoma‐derived EVs. In this study, a specific purification system is developed for Ewing sarcoma (ES)‐derived EVs by coupling covalent chemistry‐mediated EV capture/release within a nanostructure‐embedded microchip. The purification platform—ES‐EV Click Chip—takes advantage of specific anti‐LINGO‐1 recognition and sensitive click chemistry‐mediated EV capture, followed by disulfide cleavage‐driven EV release. Since the device is capable of specific and efficient purification of intact ES EVs with high purity, ES‐EV Click Chip is ideal for conducting downstream functional studies of ES EVs. Absolute quantification of the molecular hallmark of ES (i.e., EWS rearrangements) using reverse transcription Droplet Digital PCR enables specific quantification of ES EVs. The purified ES EVs can be internalized by recipient cells and transfer their mRNA cargoes, exhibiting their biological intactness and potential role as biological shuttles in intercellular communication.


  • Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer

    by Jiantong Dong, Ryan Y. Zhang, Na Sun, Matthew Smalley, Zipeng Wu, Anqi Zhou, Shih-Jie Chou, Yu Jen Jan, Peng Yang, Lirong Bao, et al.

    Tumor-derived extracellular vesicles (EVs) present in bodily fluids are emerging liquid biopsy markers for non-invasive cancer diagnosis and treatment monitoring. Because the majority of EVs in circulation are not of tumor origin, it is critical to develop new platforms capable of enriching tumor-derived EVs from the blood. Herein, we introduce a biostructure-inspired NanoVilli Chip, capable of highly efficient and reproducible immunoaffinity capture of tumor-derived EVs from blood plasma samples. Anti-EpCAM-grafted silicon nanowire arrays were engineered to mimic the distinctive structures of intestinal microvilli, dramatically increasing surface area and enhancing tumor-derived EV capture. RNA in the captured EVs can be recovered for downstream molecular analyses by reverse transcription Droplet Digital PCR. We demonstrate that this assay can be applied to monitor the dynamic changes of ROS1 rearrangements and epidermal growth factor receptor T790M mutations that predict treatment responses and disease progression in non-small cell lung cancer patients.